Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedJun 23, 2026
DataAggregated Company Financials
Companies1402
  • 7D-1.0%
  • 3M5.6%
  • 1Y15.7%
  • YTD-2.4%

Over the last 7 days, the Healthcare industry has dropped 1.8%, driven by Eli Lilly declining 2.4%. This takes the industry's 12 month performance to a gain of 15%. Earnings are forecast to grow by 18% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 23 Jun 2026US$6.4tUS$3.3tUS$121.7b23.1x52.4x1.9x
Thu, 21 May 2026US$6.2tUS$3.3tUS$122.5b23.2x51x1.9x
Sat, 18 Apr 2026US$6.2tUS$3.3tUS$121.2b24x51.5x1.9x
Mon, 16 Mar 2026US$6.2tUS$3.3tUS$124.6b24.3x49.9x1.9x
Wed, 11 Feb 2026US$6.5tUS$3.3tUS$126.9b27.3x51.3x2x
Fri, 09 Jan 2026US$6.7tUS$3.2tUS$135.9b26.7x49.3x2.1x
Sun, 07 Dec 2025US$6.4tUS$3.2tUS$133.6b25.9x47.8x2x
Tue, 04 Nov 2025US$6.0tUS$3.1tUS$134.5b26x44.4x1.9x
Thu, 02 Oct 2025US$5.8tUS$3.1tUS$137.7b24.7x42.1x1.9x
Sat, 30 Aug 2025US$5.7tUS$3.1tUS$137.2b23.4x41.3x1.8x
Mon, 28 Jul 2025US$5.6tUS$3.1tUS$128.1b24.6x43.8x1.8x
Wed, 25 Jun 2025US$5.5tUS$3.0tUS$127.5b24.7x43.1x1.8x
Fri, 23 May 2025US$5.3tUS$3.0tUS$126.7b22.6x42.2x1.8x
Sun, 20 Apr 2025US$5.3tUS$2.6tUS$97.6b24.8x54.1x2x
Tue, 18 Mar 2025US$5.7tUS$2.6tUS$74.8b26.7x75.6x2.1x
Thu, 13 Feb 2025US$5.8tUS$2.6tUS$84.4b26.1x69.1x2.2x
Sat, 11 Jan 2025US$5.9tUS$2.9tUS$78.8b27.6x74.6x2x
Mon, 09 Dec 2024US$6.1tUS$2.9tUS$77.6b28.7x78.2x2.1x
Wed, 06 Nov 2024US$6.1tUS$2.9tUS$74.9b28.8x81.9x2.1x
Fri, 04 Oct 2024US$6.2tUS$2.8tUS$60.0b30.1x103.3x2.2x
Sun, 01 Sep 2024US$6.3tUS$2.8tUS$60.3b32.2x105x2.2x
Tue, 30 Jul 2024US$6.4tUS$2.8tUS$60.8b32.1x105x2.2x
Thu, 27 Jun 2024US$6.2tUS$2.8tUS$62.4b29.9x99.4x2.2x
Sat, 25 May 2024US$6.2tUS$2.8tUS$64.1b30.9x96.1x2.2x
Mon, 22 Apr 2024US$5.9tUS$2.8tUS$84.6b30.2x70x2.1x
Wed, 20 Mar 2024US$6.3tUS$2.8tUS$84.2b31.8x74.4x2.3x
Fri, 16 Feb 2024US$6.2tUS$2.8tUS$82.3b30.8x75.2x2.2x
Sun, 14 Jan 2024US$6.4tUS$2.8tUS$90.8b32.2x70.2x2.3x
Tue, 12 Dec 2023US$6.0tUS$2.8tUS$91.3b30.1x65.5x2.1x
Thu, 09 Nov 2023US$5.8tUS$2.8tUS$88.8b25.8x65.1x2.1x
Sat, 07 Oct 2023US$5.9tUS$2.8tUS$98.3b26.7x59.7x2.1x
Mon, 04 Sep 2023US$6.1tUS$2.8tUS$98.7b27.4x61.9x2.2x
Wed, 02 Aug 2023US$6.0tUS$2.7tUS$98.2b28.6x61.5x2.2x
Fri, 30 Jun 2023US$6.0tUS$2.7tUS$109.9b26.5x54.5x2.2x
Price to Earnings Ratio

54.5x


Total Market Cap: US$6.0tTotal Earnings: US$109.9bTotal Revenue: US$2.7tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.4x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 52.4x which is lower than its 3-year average PE of 65.4x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 3.5% per year over the last three years.
  • Revenues for these companies have grown 7.0% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market-1.82%
Healthcare-1.04%
Biotech2.84%
Healthcare Services-1.20%
Pharma-1.94%
Life Sciences-2.20%
Medical Equipment-2.66%
Healthtech-3.77%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 53.6x.
    • Analysts expect its future annual earnings growth (16.3%) to be largely in line with prior year's earnings growth.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 25% over the next 5 years.
  • However this is lower than its past earnings growth rate of 55% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 15% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$230.013.8%
+US$14.9b		25.2%PE113x
VRTX Vertex PharmaceuticalsUS$466.793.0%
+US$3.5b		3.7%PE27.3x
MRNA ModernaUS$59.3513.8%
+US$2.9b		131.2%PS10.6x
NTRA NateraUS$228.805.5%
+US$1.7b		34.3%PS13.1x
SYRE Spyre TherapeuticsUS$100.3220.0%
+US$1.5b		583.4%PB16.9x

Latest News

PFE
US$25.08
Pfizer
7D
-3.5%
1Y
4.4%
DFTX
US$36.67
Definium Therapeutics
7D
54.3%
1Y
451.8%
RVMD
US$165.81
Revolution Medicines
7D
3.6%
1Y
314.1%
LLY
US$1,102.08
Eli Lilly
7D
-2.4%
1Y
43.0%
ABBV
US$230.01
AbbVie
7D
3.8%
1Y
25.2%
MRK
US$115.48
Merck
7D
0.5%
1Y
44.1%
UNH
US$406.68
UnitedHealth Group
7D
-1.1%
1Y
35.3%
JNJ
US$231.29
Johnson & Johnson
7D
-1.9%
1Y
52.8%
ISRG
US$402.95
Intuitive Surgical
7D
-3.3%
1Y
-21.8%
MRNA
US$59.35
Moderna
7D
13.8%
1Y
131.2%
Analysis Article • Jun 21

Moderna (MRNA) Stock Could Be 39% Overvalued After FDA Flu Vaccine Backing

Moderna (MRNA) is back in focus after a unanimous FDA advisory panel vote that its investigational mRNA flu vaccine, mFlusiva, has a favorable benefit risk profile in adults 50 and older. See our latest analysis for Moderna. Moderna’s recent regulatory win has arrived after a sharp rebound in the stock, with a 1-year total shareholder return of 146.95% and a year to date share price return of 107.26%, while the 3 and 5 year total shareholder returns remain significantly lower. This suggests...
NTRA
US$228.80
Natera
7D
5.5%
1Y
34.3%
Analysis Article • Jun 20

Natera (NTRA) Stock Could Be 11.3% Undervalued After Prospera Transplant Data

Natera (NTRA) is back in focus after new transplant data at the 2026 American Transplant Congress linked its Prospera test to future adverse outcomes even when biopsies are negative, alongside fresh collaboration headlines. See our latest analysis for Natera. The recent Prospera data and new transplant collaborations have arrived alongside a strong run in Natera’s shares, with a 30-day share price return of 12.93% and a 1-year total shareholder return of 34.65%. The 3-year total shareholder...
BSX
US$44.33
Boston Scientific
7D
-5.2%
1Y
-56.7%
Analysis Article • Jun 19

Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance

Boston Scientific (BSX) shares have come under pressure after the company issued 2026 guidance that fell short of market expectations, with investors focusing on slowing revenue growth in its electrophysiology segment. See our latest analysis for Boston Scientific. At a share price of $45.29, Boston Scientific has seen pressure build, with the 30 day share price return down 20.28% and the year to date share price return down 52.18%. The 1 year total shareholder return is down 55.32%, pointing...
MCK
US$744.85
McKesson
7D
-4.5%
1Y
3.2%
Analysis Article • Jun 17

McKesson (MCK) Stock Could Be 17.3% Undervalued After Loan Deal And Buybacks

McKesson (MCK) stock is in focus after a cluster of recent moves, including a US$2.25b senior secured term loan maturing in 2032, a minority sale in Medical-Surgical Solutions and ongoing share repurchases. See our latest analysis for McKesson. After a weaker quarter and a pullback that left the 90 day share price return down 14.66% and the year to date share price return down 4.62%, McKesson still has a 1 year total shareholder return of 8.87% and a very large 5 year total shareholder...
VRTX
US$466.79
Vertex Pharmaceuticals
7D
3.0%
1Y
3.7%
Narrative Update • Jun 17

VRTX: Kidney Franchise And Pipeline Expansion Will Drive Future Stock Upside

Vertex Pharmaceuticals' latest narrative update reflects a modest recalibration in analyst price targets, with figures such as Truist's move to $542 and Wells Fargo's lift to $550 framed around analysts' view that the emerging kidney franchise can grow into blockbuster assets and broaden the company's portfolio. Analyst Commentary Recent Street research on Vertex Pharmaceuticals highlights a generally constructive tone, with bullish analysts pointing to the expanding kidney franchise and a series of upward price target revisions as key supports for the stock's valuation and growth narrative.
TMO
US$464.01
Thermo Fisher Scientific
7D
-2.0%
1Y
15.9%
Analysis Article • Jun 17

Thermo Fisher Scientific (TMO) Stock Could Be 23% Below Fair Value After Neutral Rating

Piper Sandler’s new Neutral rating on Thermo Fisher Scientific (TMO), alongside a Material Transfer Agreement with Polymer Factory Sweden AB, has drawn fresh attention to how the stock reflects industry conditions and emerging technology partnerships. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s latest share price of $472.63 sits against a mixed backdrop, with the stock down 20.23% on a year to date share price basis but delivering a 21.55% total...
SYRE
US$100.32
Spyre Therapeutics
7D
20.0%
1Y
583.4%